Literature DB >> 24367921

Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes.

Juliana C Small1, Raj K Kurupati, Xiangyang Zhou, Ang Bian, Emily Chi, Yan Li, Zhiquan Xiang, Hildegund C J Ertl.   

Abstract

Here we describe a series of replication-defective adenovirus vectors designed to express transgene products from two expression cassettes placed into the deleted E1 and E3 domains. Vectors that contained an E1 cassette with a cytomegalovirus promoter in the forward orientation and an E3 cassette with the chicken β-actin promoter in the reverse orientation grew to acceptable yields and expressed both transgenes. Additionally, they elicited immune responses to both transgene products. Levels of expression and the vectors' immunogenicity were influenced by the presence of regulatory elements shared between the two expression cassettes. Specifically, vectors that carried the same intron and enhancer in both expression cassettes could be rescued and expanded, but they were poorly immunogenic. Deletion of the enhancer or both the enhancer and the intron from the E3 cassette increased T- and B-cell responses to both transgene products.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24367921      PMCID: PMC3996997          DOI: 10.1089/hum.2013.216

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  27 in total

Review 1.  Subversion of host defense mechanisms by adenoviruses.

Authors:  H G Burgert; Z Ruzsics; S Obermeier; A Hilgendorf; M Windheim; A Elsing
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

2.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.

Authors:  A Irie; K Matsumoto; B Anderegg; H Kuruma; M Kashani-Sabet; K J Scanlon; T Uchida; S Baba
Journal:  Cancer Gene Ther       Date:  2006-03       Impact factor: 5.987

4.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

5.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Authors:  J E Ledgerwood; P Costner; N Desai; L Holman; M E Enama; G Yamshchikov; S Mulangu; Z Hu; C A Andrews; R A Sheets; R A Koup; M Roederer; R Bailer; J R Mascola; M G Pau; N J Sullivan; J Goudsmit; G J Nabel; B S Graham
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

6.  Adenovirus-mediated dual gene expression of human interleukin-10 and hepatic growth factor exerts protective effect against CCl4-induced hepatocyte injury in rats.

Authors:  Hong Qiu; Yan Yan; Jicheng Xing; Yuerong Zhu; Lin Fang; Xiangrong Cao; Changqing Su
Journal:  Dig Dis Sci       Date:  2012-03-08       Impact factor: 3.199

7.  Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1.

Authors:  Lei Ye; Husnain Kh Haider; Shujia Jiang; Ru San Tan; Ruowen Ge; Peter K Law; Eugene K W Sim
Journal:  Eur J Heart Fail       Date:  2006-07-07       Impact factor: 15.534

8.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Authors:  Andrew T Catanzaro; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Lin Gu; Julie E Martin; Laura Novik; Bimal K Chakrabarti; Bryan T Butman; Jason G D Gall; C Richter King; Charla A Andrews; Rebecca Sheets; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

9.  Chimpanzee-origin adenovirus vectors as vaccine carriers.

Authors:  N Tatsis; L Tesema; E R Robinson; W Giles-Davis; K McCoy; G P Gao; J M Wilson; H C J Ertl
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

10.  Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs.

Authors:  M V Chengalvala; B M Bhat; R Bhat; M D Lubeck; S Mizutani; A R Davis; P P Hung
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

View more
  2 in total

1.  Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Authors:  Marija Vujadinovic; Kerstin Wunderlich; Benoit Callendret; Marina Koning; Mark Vermeulen; Barbara Sanders; Esmeralda van der Helm; Adile Gecgel; Dirk Spek; Karin de Boer; Masha Stalknecht; Jan Serroyen; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn; Jerome Custers; Jort Vellinga
Journal:  Hum Gene Ther       Date:  2017-11-30       Impact factor: 5.695

2.  Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position.

Authors:  M Suzuki; S Kondo; Z Pei; A Maekawa; I Saito; Y Kanegae
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.